Clinical Trials Logo

Leiomyosarcoma clinical trials

View clinical trials related to Leiomyosarcoma.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT05174455 Withdrawn - Clinical trials for Metastatic Leiomyosarcoma

Niraparib for the Treatment of Leiomyosarcoma

Start date: December 1, 2023
Phase: Phase 2
Study type: Interventional

This phase II trial tests whether niraparib works to shrink tumor in patients with leiomyosarcoma. Niraparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy.

NCT ID: NCT05116800 Withdrawn - Soft Tissue Sarcoma Clinical Trials

Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma

Start date: March 1, 2022
Phase: Phase 2
Study type: Interventional

This is an open label, two-stratum, phase 2 clinical trial evaluating the efficacy of 9-ING-41 in combination with gemcitabine/docetaxel in patients ≥10 years of age with advanced sarcoma. 9-ING-41 in combination with gemcitabine and docetaxel will lead to sustained disease control and/or increase the rates of objective response in patients with unresectable or metastatic soft tissue and bone sarcomas.

NCT ID: NCT04906876 Withdrawn - Sarcoma Clinical Trials

A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas

Start date: September 2021
Phase: Phase 2
Study type: Interventional

9-ING-41 in combination with gemcitabine and docetaxel will lead to sustained disease control and/or increase the rates of objective response in patients with unresectable or metastatic soft tissue and bone sarcomas. This is an open label, two-stratum, phase 2 clinical trial evaluating the efficacy of 9-ING-41 in combination with gemcitabine/docetaxel in patients ≥10 years of age with advanced sarcoma. Stratum A: Patients with advanced soft tissue sarcoma previously treated with 0-3 prior lines of systemic therapy will receive 9-ING-41 twice weekly with gemcitabine on days 1 and 8 and docetaxel on day 8 of a 21-day cycle until disease progression or unacceptable toxicity. Stratum B: Patients with relapsed or refractory bone sarcoma previously treated with at least one line of systemic therapy will receive 9-ING-41 twice weekly with gemcitabine on days 1 and 8 and docetaxel on day 8 of a 21-day cycle until disease progression or unacceptable toxicity. Disease response assessment will be performed every 2 cycles (6 weeks) for the first 8 cycles (24 weeks), then every 12 weeks thereafter.

NCT ID: NCT03773510 Withdrawn - Leiomyosarcoma Clinical Trials

Study on Leiomyosarcoma, Liposarcomas and Synovial Sarcoma With Trabectedin

TRADITIONS
Start date: February 28, 2019
Phase: Phase 3
Study type: Interventional

Two arm, randomized, open-label study, to determine the best time to secondary resistance between responding patients who discontinue treatment and resumed Trabectedin at the time of progression versus patients who continued treatment until progression. T

NCT ID: NCT03437070 Withdrawn - Leiomyosarcoma Clinical Trials

Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma

Start date: June 2019
Phase: Phase 1
Study type: Interventional

This study seeks to determine if addition of trabectedin (T) to combination doxorubicin (D) and olaratumab (O), is feasible and tolerable with antitumor activity in metastatic or recurrent Leiomyosarcomas (LMS) patients who have limited therapeutic options.

NCT ID: NCT02378142 Withdrawn - Clinical trials for Uterine Leiomyosarcoma

Pazopanib for Treating Uterine Leiomyosarcoma

Start date: March 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to test any good and bad effects of the study drug pazopanib.